Washington University School of Medicine in St. Louis has pieced together a pioneering new study that will help put a new theory on preventing Alzheimer's to a definitive test. And the outcome could help pave the way for a megablockbuster approach to treating a disease that afflicts millions.
That dark cloud you've been watching form around the late-stage Alzheimer's drug development field has come equipped with a bright silver lining for Roche.
Here's an interesting number for anyone interested in the risks and rewards of drug development: Two of every three analysts and fund managers recently queried by the ISI Group say they expect that new Alzheimer's drugs in late-stage testing at Eli Lilly and Pfizer/J&J will fail.
Roche has taken the first big clinical step in a long journey it hopes will lead to a mega-blockbuster market. The pharma giant says that a small, early-stage study of its experimental Alzheimer's